Posts Tagged ‘vaccines’

EPA Study: Autism Boom Began in 1988, Environmental Factors Are Assumed

EPA Study: Autism Boom Began in 1988, Environmental Factors Are Assumed

Courtesy of David Kirby at The Huffington Post 

If it seems like most of the people you know with autism are 22 or younger, that’s because most people diagnosed with autism were born after 1987. A recent US EPA study has found a distinct "changepoint" year – or spike – in autism in California and elsewhere and concludes that it would be "prudent to assume that at least some portion of this increase is real and results from environmental factors."

"In the Danish, California, and worldwide data sets, we found that an increase in autism disorder cumulative incidence began about (the birth cohort years) 1988-1989," wrote the authors Michael E. Mc Donald and John F. Paul, of the EPA’s National Health and Environmental Effects Research Laboratory.

"Although the debate about the nature of increasing autism continues," they added, "the potential for this increase to be real and involve exogenous (external) environmental stressors exists."

But it was the distinct timing in the increase of autism – the birth of an epidemic, as many believe – that was most notable, and which "may help in screening for potential candidate environmental stressors."

"The calculated year was determined to be significant," the EPA scientists said. The rate of increase before 1988 "was significantly different" than the rate after that year (the "postchangepoint," in epidemiology parlance). In California, the rate spiked from 5.7-per-10,000 before the changepoint, to 20.8-per 10,000 in its wake, and the worldwide dataset showed a similar jump (from 6.0 to 24.2). In Denmark, the rise was even more dramatic, though total incidence was only a fraction of that in the US: from 0.6 to 6.6.

(A study in Japan from 1988-1996 showed continuously increasing autism rates, but no calculable changepoint year – please see the full report for a discussion on study limitations).

So why would rates more than triple in California kids born before and after 1988? Is…
continue reading


Tags: , , , , , , , , , ,




Double-Edged Sword: Swine Flu and Vaccines

By guest author Terry Doherty and Ilene, your editor

Terry Doherty is the Research Program Coordinator in the Depts of Biomedical Sciences and Academic Affairs at Cedar Sinai in Los Angeles, California.

Double-Edged Sword: Swine Flu and Vaccines

There’s plenty that is unknown about the swine flu and the swine flu vaccine.  If searches on the internet are any indication, deciding whether or not to be vaccinated may be a tough, emotionally charged decision for many people.  So how – without having the background to write a swine flu grant proposal, conduct the research, and get the thing published in the New England Journal of Medicine – do we decide whether or not to get a swine flu shot?  

One way is to attempt to evaluate and weigh the risks of the vaccine against the risks of the flu.  That is how I approach the subject, but it’s easier said than done.  As is often the case with medical interventions, the risks are not fully known. And even if we could carefully assess the risks, our underlying assumptions may be wrong.  Percent risks are averages collected by studying large populations.  We may not be one of the statistical average.  Then there are the gaps in the available data, and own biases and belief systems.  Our view of the world affects our analysis and often we are not even aware of how large of an effect those biases may play.   

In Vaccine War: Autism, Flu and Science, TIME, Maia Szalavitz discusses how emotion and biases play a large part in our risk-benefit assessments:

Just in time for the national roll-out of the new H1N1 flu vaccine, Wired Magazine and the Atlantic have weighed in on the ongoing vaccine war: Wired has a profile of Paul Offit, a vaccine researcher and pediatrician who has consistently spoken out in favor of vaccination and pointed to the lack of evidence linking vaccines and autism; the Atlantic checks in with a piece questioning the science suggesting that flu vaccines and antiviral drugs prevent people from dying.

Both articles have elicited heated debate all over the Web: Amy Wallace, who wrote Wired’s piece, excerpted below, has received vitriolic criticism and attacks from vaccine opponents, setting records for page views…

This debate over vaccination doesn’t seem likely to end any time soon. For critics, vaccines…
continue reading


Tags: , , , , , , , , , , , ,




In Germany, A Better H1N1 Vaccine For Politicians?

For additional reading on the swine flu vaccine situation in Germany, see the article at the end translated by my friend Bob, in red.  Thank you Bob. - Ilene

In Germany, A Better H1N1 Vaccine For Politicians?

vaccinesBy Tristana Moore / Berlin, Courtesy of TIME

Critics are calling it a two-tier health system — one for the politically well-connected, another for the hoi polloi. As Germany launched its mass vaccination program against the H1N1 flu virus on Monday, the government found itself fending off accusations of favoritism by offering one vaccine believed to have fewer side effects to civil servants, politicians and soldiers, and another potentially riskier vaccine to everyone else. The government had hoped that Germans would rush to health clinics to receive vaccinations against the rapidly spreading disease, but the rising anger over the different doses may now cause many people to shy away.

Amid growing fears over a possible global flu pandemic, the German government prepared for its mass vaccination campaign earlier this year by ordering 50 million doses of the Pandemrix vaccine, which would be enough for a double dose for 25 million people, around a third of the population. The vaccine, manufactured by GlaxoSmithKline, contains an immune-enhancing chemical compound, known as an adjuvant, whose side effects are not yet entirely known. Then, after a report was leaked to the German media last week, the Interior Ministry confirmed that it had ordered a different vaccine, Celvapan, for government officials and the military. Celvapan, which is made by the U.S. pharmaceutical giant Baxter, does not contain an adjuvant and is believed to have fewer side effects than Pandemrix.

Anger at the news was widespread in Germany. "If mass vaccination is considered to be necessary, then everyone should be treated the same way," says Birgitt Bender, the health spokeswoman for the Green Party. Ulrike Mascher, head of the VdK social welfare association, said giving government officials a different vaccine from the rest of the population sent the "wrong signal" and gave many people "the impression that they are second-class patients." A story on the front page of the mass-circulation Bild newspaper accused the government of giving "second-class medicine" to regular Germans.

Doctors and medical experts are divided over the safety of Pandemrix. While some say it’s the best vaccine available, others have serious misgivings about it. "The Pandemrix vaccine can’t be recommended…
continue reading


Tags: , , , , ,




New Study: Hepatitis B Vaccine Triples the Risk of Autism in Infant Boys

Weekend off-topic reading.  I found this fascinating. - Ilene  

New Study: Hepatitis B Vaccine Triples the Risk of Autism in Infant Boys

Courtesy of David Kirby writing at the Huffington Post

"The science is largely complete. Ten epidemiological studies have shown MMR vaccine doesn’t cause autism; six have shown thimerosal doesn’t cause autism."-- Dr. Paul Offit, "Autism’s False Prophets"

"16 studies have shown no causal association between vaccines and autism, and these studies carry weight in the scientific industry."-- Dr. Nancy Snyderman, NBC Today Show Medical Editor

Conventional wisdom holds that the autism-vaccine question has been "asked and answered," and that at least 16 large, well-constructed epidemiological studies have thoroughly addressed and debunked any hypothesis that childhood vaccination is in any way associated with an increased risk for autism spectrum disorders.

But there are several critical flaws in such an oversimplified generalization, and they are rarely given close examination by public health experts or members of the media.

To begin with, it is unscientific and perilously misleading for anyone to assert that "vaccines and autism" have been studied and that no link has been found. That’s because the 16 or so studies constantly cited by critics of the hypothesis have examined just one vaccine and one vaccine ingredient.

And, the population studies themselves have had critical design flaws and limitations.

The current US childhood immunization schedule calls for 28 injections with 11 different vaccines against 15 different diseases by two years of age. Of those 11 vaccines, only the Measles-Mumps-Rubella (MMR) shot has been studied in association with autism, (although a CDC study of an MMR-plus-chickenpox vaccine did show that the risk for febrile seizures in infants was doubled.) Meanwhile, those 11 vaccines contain scores of ingredients, only one of which, thimerosal, has ever been tested in association with autism.

It is illogical to exonerate all vaccines, all vaccine ingredients, and the total US vaccine program as a whole, based solely on a handful of epidemiological studies of just one vaccine and one vaccine ingredient. It is akin to claiming that every form of animal protein is beneficial to people, when all you have studied is fish.

Now, a new study has shown that giving Hepatitis B vaccine to newborn baby boys may triple the risk of developing an autism spectrum disorder.

An abstract of the study was published in the September, 2009…
continue reading


Tags: , , , , , , ,




Swine Flu Vaccine: Watching For Side Effects

The decision regarding whether or not to get vaccinated for swine flu, or have your kids vaccinated, may be easy for some, but is not for others. It depends on how you perceive and value the risks. As is often the case with medical interventions, the risks are not fully known or understood. Even if you’re lucky enough to believe you’ve obtained valid risk percentages to compare, you cannot truly know whether your assumptions accurately reflect reality. And your numbers certainly don’t factor in the unknown.

So as the swine flu vaccine program gets underway, several government-sponsored projects will attempt to determine how safe the vaccine really is. We have a rather unique opportunity to learn a lot more while serving as subjects in this grand experiment.

Go ahead, leave comments and share your thoughts… – Ilene

Swine Flu Vaccine: Watching For Side Effects

(WASHINGTON) — More than 3,000 people a day have a heart attack. If you’re one of them the day after your swine flu shot, will you worry the vaccine was to blame and not the more likely culprit, all those burgers and fries?

The government is starting an unprecedented system to track possible side effects as mass flu vaccinations begin next month. The idea is to detect any rare but real problems quickly, and explain the inevitable coincidences that are sure to cause some false alarms.

"Every day, bad things happen to people. When you vaccinate a lot of people in a short period of time, some of those things are going to happen to some people by chance alone," said Dr. Daniel Salmon, a vaccine safety specialist at the Department of Health and Human Services.

Health authorities hope to vaccinate well over half the population in just a few months against swine flu, which doctors call the 2009 H1N1 strain. That would be a feat. No more than 100 million Americans usually get vaccinated against regular winter flu, and never in such a short period.

How many will race for the vaccine depends partly on confidence in its safety. The last mass inoculations against a different swine flu, in 1976, were marred by reports of a rare paralyzing condition, Guillain-Barre syndrome.

"The recurring question is, ‘How…
continue reading


Tags: , , , , , , ,




 
 
 

Zero Hedge

FDA Approves Gilead's Remdesivir To Treat COVID-19 Despite Data Showing Drug Doesn't Work

Courtesy of ZeroHedge View original post here.

Despite reams of data from an international WHO study raising serious questions about its efficacy, the FDA has finally approved the use of Gilead Science's remdesivir - a powerful antiviral originally developed to treat ebola - for the treatment of COVID-19, making it the first such drug approved to treat the virus in the US.

The FDA first granted the drug emergency authorization in May, allowing hospitals and ...



more from Tyler

Phil's Favorites

SPINNING WHEEL

 

SPINNING WHEEL

Courtesy of Almost Daily Grant's

Top of the heap no more. International Business Machines Corp. reported third quarter earnings on Monday, including $17.56 billion in revenues.  That’s down 2.6% from a year ago and 3.1% sequentially and the weakest result since the first quarter of 1997. 

While $2.58 in headline earnings per share was down 4% from a year ago, a series of salutary one-time adjustments spruced up that figure, which was 27% above the $1.89 per share derived from generally accepted accounting principles.  Even those GAAP results were flattered by a meager 7% corporate tax rate.  In 1985, when then-dominant IBM commanded a 6.4% share of the market cap-weighted S&P 500 (a record single-stock concentrati...



more from Ilene

Politics

How to track your mail-in ballot

 

How to track your mail-in ballot

Make sure you know when your ballot is arriving, and whether it’s been accepted for counting back at your election office. erhui1979/DigitalVision Vectors via Getty Images

Courtesy of Steven Mulroy, University of Memphis

Many voters who want to participate in the election by mail are concerned about when they’ll receive their ballot – and whether it will get back in time to be counted.

The pandemic has caused interest in ...



more from Politics

ValueWalk

A New Judge At The Expense Of COVID Relief

By Ankur Shah. Originally published at ValueWalk.

What’s At Stake for Small Businesses with another Conservative Supreme Court Confirmation?

Q3 2020 hedge fund letters, conferences and more

Press Call - Monday - 2pm ET - Register

Senate Wants A New Judge At ...

more from ValueWalk

Biotech/COVID-19

Disney's pivot to streaming is a sign of severe COVID economic crisis still to come

 

Image by Eiji Kikuta from Pixabay

 

Disney’s pivot to streaming is a sign of severe COVID economic crisis still to come

Courtesy of Hamza Mudassir, Cambridge Judge Business School

Disney has announced a significant restructuring o...



more from Biotech/COVID-19

Kimble Charting Solutions

Doc Copper/Gold Indicator Breaking Out Again?

Courtesy of Chris Kimble

The Doc Copper/Gold ratio broke above a 2-year falling channel back in 2016 at (1). Following this breakout, it rallied for the next year. During that year, Copper related assets did very well!

The ratio peaked in the summer of 2018 and created a series of lower highs over the past two years.

The strength of late has the ratio attempting to break above dual resistance at (2).

If the ratio continues to push higher and succeeds in breaking out, Copper, Basic Materials (XLB), and ...



more from Kimble C.S.

Chart School

Dow Gann Angle Update

Courtesy of Read the Ticker

Time to see what happens to the Dow post US elections.

The Dow Gann Angle Target 3 (from 2007 top) is on the table, and what a ride that will be. The FED went BRRRRR is all the fundamental news you need to know. Gann angles are very good tool to see how the masses are pushing price.


Click for popup. Clear your browser cache if image is not showing.



The last two US elections saw Bitcoin and the DOW rally well for 6 months, due to stimulus. The most bearish 2020 US Election case for the markets is a Biden win with the Senate and Congress controlled by the Democrats, somehow this blog feels that is very unlikely. So what could go wrong!


...

more from Chart School

Digital Currencies

Bitcoin: the UK and US are clamping down on crypto trading - here's why it's not yet a big deal

 

Bitcoin: the UK and US are clamping down on crypto trading – here's why it's not yet a big deal

Where there’s a bit there’s a writ. Novikov Aleksey

Courtesy of Gavin Brown, University of Liverpool

The sale and promotion of derivatives of bitcoin and other cryptocurrencies to amateur investors is being banned in the UK by the financial regulator, the Financial Conduct Authority (FCA). It is a...



more from Bitcoin

Mapping The Market

COVID-19 Forces More Than Half of Asset Management Firms to Accelerate Adoption of Digital Marketing Technology

By Jacob Wolinsky. Originally published at ValueWalk.

There is no doubt that the use of technology to support client engagement initiatives brings both opportunities and threats but this has been brought into sharp focus this year with the COVID-19 pandemic.

The crisis has brought to the fore the need for firms to enable flexibility in client engagement – the expectation that providers will communicate to clients on their terms, at their speed and frequency and on their preferred channels, is now a given. This is even more critical when clients are experiencing unparalleled anxiety from both market conditions and their own personal circumstances.

...

more from M.T.M.

The Technical Traders

Adaptive Fibonacci Price Modeling System Suggests Market Peak May Be Near

Courtesy of Technical Traders

Our Adaptive Fibonacci Price Modeling system is suggesting a moderate price peak may be already setting up in the NASDAQ while the Dow Jones, S&P500, and Transportation Index continue to rally beyond the projected Fibonacci Price Expansion Levels.  This indicates that capital may be shifting away from the already lofty Technology sector and into Basic Materials, Financials, Energy, Consumer Staples, Utilities, as well as other sectors.

This type of a structural market shift indicates a move away from speculation and towards Blue Chip returns. It suggests traders and investors are expecting the US consumer to come back strong (or at least hold up the market at...



more from Tech. Traders

Lee's Free Thinking

Texas, Florida, Arizona, Georgia - The Branch COVIDIANS Are Still Burning Down the House

 

Texas, Florida, Arizona, Georgia – The Branch COVIDIANS Are Still Burning Down the House

Courtesy of Lee Adler, WallStreetExaminer 

The numbers of new cases in some of the hardest hit COVID19 states have started to plateau, or even decline, over the past few days. A few pundits have noted it and concluded that it was a hopeful sign. 

Is it real or is something else going on? Like a restriction in the numbers of tests, or simply the inability to test enough, or are some people simply giving up on getting tested? Because as we all know from our dear leader, the less testing, the less...



more from Lee

Insider Scoop

Economic Data Scheduled For Friday

Courtesy of Benzinga

  • Data on nonfarm payrolls and unemployment rate for March will be released at 8:30 a.m. ET.
  • US Services Purchasing Managers' Index for March is scheduled for release at 9:45 a.m. ET.
  • The ISM's non-manufacturing index for March will be released at 10:00 a.m. ET.
  • The Baker Hughes North American rig count report for the latest week is scheduled for release at 1:00 p.m. ET.
...

http://www.insidercow.com/ more from Insider

Promotions

Free, Live Webinar on Stocks, Options and Trading Strategies

TODAY's LIVE webinar on stocks, options and trading strategy is open to all!

Feb. 26, 1pm EST

Click HERE to join the PSW weekly webinar at 1 pm EST.

Phil will discuss positions, COVID-19, market volatility -- the selloff -- and more! 

This week, we also have a special presentation from Mike Anton of TradeExchange.com. It's a new service that we're excited to be a part of! 

Mike will show off the TradeExchange's new platform which you can try for free.  

...

more from Promotions





About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. Contact Ilene to learn about our affiliate and content sharing programs.